Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

LTGO

Latigo Biotherapeutics Inc

18.90

Aug 11 • 8:39 AM ET +0.34 (1.83%)

Healthcare Biotechnology USA Small NASD

Scroll to Statements

Index	-
Market Cap	1.14B
Enterprise Value	1.38B
Income	-
Sales	-
Book/sh	-3.99
Cash/sh	0.70
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Aug 07, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	26.83
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.23
Current Ratio	3.23
Debt/Eq	0.02
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	74.32%
Insider Trans	0.63%
Inst Own	4.20%
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.78%
SMA50	1.78%
SMA200	1.78%
Trades

Shs Outstand	63.24M
Shs Float	15.45M
Short Float	-
Short Ratio	-
Short Interest	-
52W High	22.47 -15.89%
52W Low	17.22 9.76%
Volatility	- -
ATR (14)	2.13
RSI (14)	-
Beta	-
Rel Volume	0.00
Avg Volume	1.95M
Volume	112

Perf Week	-
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-10.00%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	18.56
Price	18.90
Change %	1.83%

Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418. The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.

CEOMr. Nima Farzan M.B.A.

Chief Business Officer & CFOMs. Neha Krishnamohan

Senior Vice President of OperationsMs. Julia Chapman

Vice President of Corporate DevelopmentMs. Caroline Dougherty

Senior Vice President of DiscoveryMr. Bryan Moyer Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Foresite Capital Management V,	10% Owner	Aug 10 '26	Buy	18.00	140,000	2,520,000	2,008,024	Aug 10 08:21 PM
Tananbaum James B.	Director	Aug 10 '26	Buy	18.00	140,000	2,520,000	2,008,024	Aug 10 08:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LTGO

Latigo Biotherapeutics Inc

Upgrade your Finviz experience